Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pancreas/duodenum homeobox protein 1 (PDX1) is a homeodomain-containing transcription factor that is a master regulator of pancreatic organogenesis and a key determinant of both pancreatic β-cell development and mature function[1][2][3][4][7]. PDX1 is essential for pancreas formation, maintenance of β-cell identity, and regulation of insulin and other islet hormone genes. Loss of PDX1 function results in pancreatic agenesis in development and β-cell dysfunction or death in adults, leading to various forms of diabetes[3][4]. PDX1 is also expressed in the developing and adult duodenum, where it maintains duodenal cell differentiation[3]. Clinically, PDX1 is notable as an autoantigen in Type 1 diabetes, with circulating autoantibodies detectable in patients[5]. It is considered a major molecular target for strategies aimed at β-cell regeneration and reprogramming in diabetes therapy[5].
As a transcription factor, PDX1 is targeted in strategies for regenerative medicine, including β-cell regeneration and cellular reprogramming for diabetes treatment[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pancreas/duodenum homeobox protein 1 (PDX1).